强生公司宣布,其药物Nipocalimab的安全性特征与之前对该药物的研究结果保持一致,且未发现新的安全性信号。
强生公司宣布,其药物Nipocalimab的安全性特征与之前对该药物的研究结果保持一致,且未发现新的安全性信号。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.